ECEESPE2025 Poster Presentations Pituitary, Neuroendocrinology and Puberty (162 abstracts)
High risk of psychiatric morbidity in patients with acromegaly: a cohort study and meta-analysis
Astrid Matthesen 1 , Christian Rosendal 1,2 , Emma Christensen 1 , Helga Beckmann 1 , Frederik Klit 1,3 , Amar Nikontovic 3 , Gustav Bizik 4 , Peter Vestergaard 1,2,3 & Jakob Dal 1,2
1Aalborg University, Department of Clinical Medicine, Gistrup, Denmark; 2Aalborg University Hospital, Department of Endocrinology, Aalborg, Denmark; 3Aalborg University Hospital, Steno Diabetes Center North Denmark, Gistrup, Denmark; 4Aalborg University Hospital, Department of Psychiatry, Aalborg, Denmark
JOINT706
Introduction: Psychiatric morbidity in acromegaly is increasingly recognized. However, current studies are limited by small sample sizes and divergent Results We aimed to evaluate the risk of psychiatric morbidity in a retrospective cohort study comparing acromegaly with non-functioning pituitary adenomas (NFPAs) combined with a meta-analysis of the existing literature.
Methods: The cohort study included data from medical records analysed using Chi2-, t-tests and log-binomial regression. The meta-analysis included studies retrieved from PubMed, Embase and PsycINFO that reported risk of psychopathology in acromegaly compared to NFPA or healthy controls using a random effects model.
Results: 105 acromegaly and 211 NFPA patients were identified in the cohort study. They had similar sex distributions. Patients with acromegaly presented with smaller pituitary adenomas (17.9 ±9.9 mm vs. 22.9 ±10.6 mm, P < 0.001), more frequent pituitary surgery (89.1% vs. 60.2%, P < 0.001) and hormone replacement therapy (25.7% vs. 16.1%, P = 0.042). Acromegaly patients had higher risk of depression (RR: 1.9, CI95% [1.2;3.2], P = 0.009), and increased need of admissions to the psychiatric ward (5.7% vs. 0.5%, P = 0.006). Daily opioid use was higher in acromegaly patients with psychiatric morbidity and was associated with a diagnosis of arthropathy (P = 0.009). The risk of anxiety was indifferent with a CI95% of [0.5;4.4]. The meta-analysis (8 studies, 1,387 patients) revealed increased risks of both depression (RR: 1.8, CI95% [1.3;2.5]) and anxiety (RR: 1.9, CI95% [1.1;3.2]) in acromegaly compared to NFPAs. Likewise, the risk of depression was increased compared to healthy controls (RR: 2.5, CI95% [1.8;3.5]).
Conclusion: This study reveals a higher risk of depression and anxiety in acromegaly. This warrants increased psychiatric awareness in these patients.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more